Baker, D., Pryce, G., James, L. K., Marta, M., & Schmierer, K. (2020). The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis. Multiple sclerosis and related disorders, 44, 102279. https://doi.org/10.1016/j.msard.2020.102279
Citace podle Chicago (17th ed.)Baker, David, Gareth Pryce, Louisa K. James, Monica Marta, a Klaus Schmierer. "The Ocrelizumab Phase II Extension Trial Suggests the Potential to Improve the Risk: Benefit Balance in Multiple Sclerosis." Multiple Sclerosis and Related Disorders 44 (2020): 102279. https://doi.org/10.1016/j.msard.2020.102279.
Citace podle MLA (9th ed.)Baker, David, et al. "The Ocrelizumab Phase II Extension Trial Suggests the Potential to Improve the Risk: Benefit Balance in Multiple Sclerosis." Multiple Sclerosis and Related Disorders, vol. 44, 2020, p. 102279, https://doi.org/10.1016/j.msard.2020.102279.